In the context of bladder cancer, Ma et al. [59] demonstrated an increase in CD69 expression on activated T cells (ATC) when treated with an anti-CD3-B7-H3 bispecific antibody (B7-H3Bi-Ab). This evidence concerns the gene CD69 and urinary bladder cancer.